Guorong Zou

机构：Xuzhou Medical College, Zhejiang Cancer Hospital, Panyu District Central Hospital, Hangzhou Cancer Hospital, Guangzhou Medical University · ORCID：0000-0002-6335-2420

发表论文 52 篇 · 总被引 891 次 · h-index 14

代表论文

• Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial (2024 · The Lancet · 被引 186)
• Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma (2025 · JAMA · 被引 73)
• Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma (2025 · JAMA · 被引 29)
• Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials (2024 · Signal Transduction and Targeted Therapy · 被引 23)
• Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study (2024 · Signal Transduction and Targeted Therapy · 被引 19)
• Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial (2023 · EClinicalMedicine · 被引 19)